Article info
PDFCorrespondence response
Response to: ‘Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial’’ by Wang et al
- Correspondence to Dr Jacques-Eric Gottenberg, Service de Rhumatologie, CHU de Strasbourg, Centre National de Référence pour les Maladies Auto-Immunes Systémiques Rares Est Sud-Ouest RESO, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France; jacques-eric.gottenberg{at}chru-strasbourg.fr
Citation
Response to: ‘Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial’’ by Wang et al
Publication history
- Received January 11, 2021
- Accepted January 12, 2021
- First published January 27, 2021.
Online issue publication
February 10, 2023
Article Versions
- Previous version (27 January 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.